Glenmark Pharmaceuticals Ltd.

36th JP Morgan Healthcare Conference

January 2018
Disclaimer

These materials have been prepared by Glenmark Pharmaceuticals (“Glenmark” or the “Company”) solely for informational purposes, and are strictly confidential and may not be taken away, reproduced or redistributed to any other person. By attending this presentation, participants agree not to remove this document from the conference room where such documents are provided without express written consent from the Company. Participants agree further not to photograph, copy or otherwise reproduce these materials at any point of time during the presentation or while in your possession. By attending this presentation, you are agreeing to be bound by the foregoing restrictions. Any failure to comply with these restrictions may result in a violation of applicable laws and commencement of legal proceedings against you.

It is not the Company’s intention to provide, and you may not rely on these materials as providing, a complete or comprehensive analysis of the Company’s financial position or prospects. The information contained in these materials has not been independently verified and is subject to verification, completion and change without notice. The information contained in these materials is current as of the date hereof and is subject to change without notice, and its accuracy is not guaranteed. The Company is not under any obligation to update or keep current the information contained in these materials subsequent to the date hereof. Accordingly, no representation or warranty, express or implied, is made or given by or on behalf of the Company, or any of its directors and affiliates or any other person, as to, and no reliance should be placed for any purposes whatsoever on, the fairness, accuracy, completeness or correctness of, or any errors or omissions in, the information contained in these materials. Neither the Company, its directors, officers or employees nor any other person accept any liability whatsoever for any loss howsoever arising from any use of these materials or their contents or otherwise arising in connection therewith.

These materials contain historical information of the Company which should not be regarded as an indication of future performance or results. These materials may also contain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. These forward-looking statements reflect the Company’s current views with respect to future events and are not a guarantee of future performance or results. Actual results, performance or achievements of the Company may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such forward-looking statements are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future, and must be read together with such assumptions. Predictions, projections or forecasts of the economy or economic trends of the markets are not necessarily indicative of the future or likely performance of the Company, and the forecast financial performance of the Company is not guaranteed. No reliance should be placed on these forward-looking statements, if any.
Agenda

Corporate Overview & Strategic Roadmap

Ryaltris™ - GSP 301

GBR 830

GBR 1302

Future Outlook
Agenda

Corporate Overview & Strategic Roadmap

Ryaltris™ - GSP 301

GBR 830

GBR 1302

Future Outlook
Evolved into a successful global organization over the last 17 years

<table>
<thead>
<tr>
<th></th>
<th>Year 2000</th>
<th>Year 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Wealth Creation</strong></td>
<td>Revenue: <strong>US$ 31 mn</strong></td>
<td>Revenue: <strong>US$ 1.4 bn</strong></td>
</tr>
<tr>
<td></td>
<td>Market Cap.: <strong>US$ 40 mn</strong></td>
<td>Market Cap: <strong>US$ 2.5 bn</strong></td>
</tr>
<tr>
<td><strong>Manufacturing Footprint</strong></td>
<td>2 formulations facilities</td>
<td>16 facilities across 4 continents; 7 approved by USFDA</td>
</tr>
<tr>
<td><strong>International Operations</strong></td>
<td>~8% of total revenues</td>
<td>&gt;70% of total revenues Present in US, EU, RCIS, LATAM etc.</td>
</tr>
<tr>
<td><strong>Innovation</strong></td>
<td>Initiation of NME research</td>
<td>Novel molecules in pipeline Focused on <strong>Oncology, Dermatology</strong> and <strong>Respiratory</strong></td>
</tr>
<tr>
<td><strong>Employees</strong></td>
<td>&lt;1,000: Primarily in India</td>
<td>&gt;13,000: Spread over 50 countries</td>
</tr>
</tbody>
</table>

Note: Revenues for FY2000 and FY2017. Market Capitalization is as of 31st March 2000 and 29th Dec 2017. FX Rate: US$1 = INR 67
Current business is spread across API, Branded and Generic Formulations

### Formulations Development and Marketing
- **Branded Formulations**
  - Brand Building in Selected Therapies

### Generics Formulations
- Substitution Model

### API Manufacturing & Marketing
- Captive Consumption and External Sales

### NME & Specialty
- Biologics and Small Molecules

#### Key geographies
- **India**
- **Russia & CIS**
- **Latin America**
- **Asia**
- **Africa**
- **CEE**
- **North America**
- **Western Europe**
- **North America**
- **Europe**
- **Japan**
- **India**
- **Latin America**

#### Key facilities
- **Switzerland**
  - Dedicated center for biologics
- **India**
  - R&D center for NCEs
  - Development hub for specialty

---

Revenue generating segments

Investing for the future
Robust growth exhibited across business segments

**Branded Formulations**
- **CAGR of 11%** over last five years
- Focused on brand building in select TAs
- Strong field force of **5,500+** globally

**Generic Formulations**
- **CAGR of 21%** over last five years
- Growth driven by niche products and selected large scale opportunities
- Leading Gx derma player in the US

**API**
- **CAGR of 19%** over last five years
- Leadership position in multiple products
- Filed ~200 DMFs in various markets

### Net Revenues (USD mn)

**Branded Formulations**
- FY13: 368
- FY14: 433
- FY15: 496
- FY16: 561
- FY17: 569

**Generic Formulations**
- FY13: 308
- FY14: 378
- FY15: 401
- FY16: 468
- FY17: 658

**API**
- FY13: 59
- FY14: 80
- FY15: 90
- FY16: 100
- FY17: 121

*Note: Net revenues in Generics Formulations chart include US, WEU and CEE, FX Rate: US$1 = INR 67 for all years*
Roadmap to evolve into an innovative research led firm and launch proprietary products

**Current position**
- 2 major geographies - US and India contributing ~60% of sales
- Generic formulation player in the US and WEU
- Branded formulation in other markets
- NME pipeline in early to mid stage of development
- Manufacturing base primarily in India

**Medium term focus (next 3-5 years)**
- US, India, Europe and API to contribute >80% of sales
- Increase presence in complex generics
- Launch specialty business in the US
- NME pipeline in advanced stage of development
- Expand manufacturing footprint

**Long term focus (next 5-10 years)**
- Launch innovative and specialty products in multiple markets
- Significant revenues from specialty and innovation segments
Focusing across the value chain in core therapy areas

Generics
- Oncology injectables launched in EMs
- Oncology injectables under FDA approval
- Ranked #2 in India
- One of the leaders in the US Gx market – Launched 30+ products
- Launched inhalers in EMs
- g-Seretide approved in Nordic; filed in others
- Generic inhalers in development for US

Specialty/Complex Gx
- Licensed g-Abraxane; FY19 filing
- Internally developing other complex generics
- Launched unique combinations in India, EMs
- Other innovative products in development
- 3 Specialty programs in pipeline for US – 1 in P3
- Unique combinations and devices in India, other EMs

Innovative Products
- Focused on bispecific and multivalent antibodies
- 2 bispecifics in Phase 1 in US and EU
- GBR 830 - targeting Atopic Dermatitis in Phase 2b
- Other autoimmune disorders under evaluation
- Assets targeting respiratory disorders in late discovery stage
- Disease Areas: COPD, IPF
## Overall NME and Specialty pipeline

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Molecule</th>
<th>MoA/Class</th>
<th>Indication</th>
<th>Pre Clinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
<th>Approval</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oncology</td>
<td>GBR 1302</td>
<td>HER2 X CD3</td>
<td>Breast Cancer Gastric Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>GBR 1342</td>
<td>CD38 X CD3</td>
<td>Multiple Myeloma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>GBR 1372</td>
<td>EGFR X CD3</td>
<td>Colorectal Cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Dermatology</td>
<td>GBR 830</td>
<td>OX40</td>
<td>Atopic Dermatitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>GRC 39815</td>
<td>Undisclosed</td>
<td>COPD, IPF</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ryaltris™</td>
<td>Steroid + AH</td>
<td>Allergic Rhinitis</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>GSP 304</td>
<td>LAMA</td>
<td>COPD</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Respiratory</td>
<td>GBR 310</td>
<td>Biosimilar</td>
<td>Asthma, CIU</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:**
1. Non-core assets include GRC 17536, GBR 900 and GBR 500. These 3 molecules and GRC 27864 are candidates for out-licensing.
2. Ryaltris™ has been conditionally accepted as the brand name for GSP 301 Nasal Spray by the U.S. Food & Drug Administration (FDA)
Expected to file 9 NDA/BLA in the next decade across NME and Specialty portfolio

<table>
<thead>
<tr>
<th>Therapy Area</th>
<th>Molecule</th>
<th>Status</th>
<th>Filing Timelines (NDA/BLA)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>2018</td>
</tr>
<tr>
<td>Respiratory</td>
<td>Ryaltris™ - GSP 301</td>
<td>Phase 3</td>
<td>✓</td>
</tr>
<tr>
<td></td>
<td>GSP 304</td>
<td>Phase 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GBR 310</td>
<td>Phase 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GRC 39815</td>
<td>Pre Clinical</td>
<td></td>
</tr>
<tr>
<td>Dermatology</td>
<td>GBR 830</td>
<td>Phase 2</td>
<td></td>
</tr>
<tr>
<td>Oncology</td>
<td>GBR 1302</td>
<td>Phase 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GBR 1342</td>
<td>Phase 1</td>
<td></td>
</tr>
<tr>
<td></td>
<td>GBR 1372</td>
<td>Pre Clinical</td>
<td></td>
</tr>
</tbody>
</table>

Note: Above timelines are based on currently planned studies. They may change based upon data, regulatory agencies feedback etc. Timelines based on Calendar years.
Agenda

- Corporate Overview & Strategic Roadmap
- Ryaltris™ - GSP 301
- GBR 830
- GBR 1302
- Future Outlook
Ryaltris™ (GSP 301) – Nasal Spray

• Ryaltris™ is a fixed-dose combination (FDC) product in a nasal spray device

• Active components of Ryaltris™ Nasal Spray (NS)
  – Olopatadine hydrochloride (antihistamine)
  – Mometasone furoate (corticosteroid)

• Both of the individual components of the FDC are approved and marketed in various markets
  – Patanase® NS and Nasonex® NS in the United States (US)

• Nasal Steroid Market opportunity
  • In Volume: ~55 mn units
  • In Value: ~USD 1.2 bn
  • Recent shift towards OTC yet the prescription market is significantly large

Source: IQVIA
Ryaltris™– Clinical Study Summary

• The clinical efficacy and safety of Ryaltris™ NS in Seasonal Allergic Rhinitis (SAR) was established in three placebo- and active-controlled, parallel-group comparative studies.
  – Ryaltris™ resulted in statistically significant and clinically relevant improvements on the primary efficacy measure (rTNSS)
  – Replicate evidence of the superiority of Ryaltris™ versus monotherapy components, as well as replicate evidence of the superiority of the individual monotherapies versus placebo, was established.
  – The safety profile of the Ryaltris™ fixed-dose combination therapy was comparable to placebo and each of its approved monotherapy constituents.

• Phase 3 study in Perennial Allergic Rhinitis (PAR) successfully completed with read-out in Fall 2017

• Successful Pre-NDA meeting held – targeting to file the NDA in H1 CY18

*Ryaltris™ NS has the potential to offer patients a safe relief of the nasal symptoms of SAR in a single, convenient drug product that encourages greater patient compliance.*
Agenda

<table>
<thead>
<tr>
<th>Corporate Overview &amp; Strategic Roadmap</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryaltris™ - GSP 301</td>
</tr>
<tr>
<td>GBR 830</td>
</tr>
<tr>
<td>GBR 1302</td>
</tr>
<tr>
<td>Future Outlook</td>
</tr>
</tbody>
</table>
GBR 830 – Asset Profile

- GBR 830 is a humanized monoclonal antibody specific for OX40 (CD134)

- Novel MOA – GBR 830 antagonizes the co-stimulatory molecule OX40 to reduce pathological immune responses
  - In many human autoimmune and inflammatory diseases OX40 and OX40L expression is increased at sites of inflammation and often correlated with disease severity
  - OX40 pathway blockade has beneficial therapeutic outcome in many autoimmune/inflammatory disease models: Arthritis, EAE, asthma/atopy, atherosclerosis, uveitis, transplant rejection, GvHD, colitis.

- Phase 2a clinical study has been completed in Atopic Dermatitis

**First-in-Class and potentially Best-in-Class due to strong immune reduction focused on memory and chronic T-cell responses but sparing naïve T-cell function**

*Source: Nature Reviews*
GBR 830 – Phase 2a Study Update

• Phase 2a, Double-Blind, Randomized, Placebo-controlled, Exploratory Multicenter Study of GBR 830 in Adult Patients with Moderate to Severe Atopic Dermatitis

• Purpose - To explore safety and the clinical effect of GBR 830 on immune response biomarkers in patients with moderate to severe Atopic Dermatitis

• Primary Endpoints
  – Safety: Treatment-emergent adverse events and serious adverse events (SAEs)
  – Biologic Response: Effect of GBR 830 on lesioned mRNA expression and pathologic epidermal phenotype in skin biopsies of moderate-to-severe AD patients
  – Histology, Thickness, Immunohistology

• Secondary Endpoints
  – Clinical Efficacy: SCORAD, EASI 50, EASI 75 and IGA
  – Pharmacokinetics

• Exploratory Analysis
GBR 830 – Phase 2a Results Summary and Conclusion

• GBR 830 was safe and well tolerated in moderate-to-severe AD patients

• 17 of 23 evaluable pts who completed the study had 50% reduction from baseline on EASI score (EASI 50) at 4 weeks after the 2nd dose

• Improvement in EASI score of GBR 830 treated patients was supported by change in SCORAD

• Most common treatment-related adverse event was headache, with no clinically meaningful differences between GBR 830 and placebo (4 percent and 6 percent, respectively).

Positive outcome of the 201 POC study met decision criteria to advance clinical development for GBR 830
• Initiation of a Phase 2b study in AD scheduled in H1 CY 2018
• Initiation of a Phase 2 exploratory study in SLE
Agenda

Corporate Overview & Strategic Roadmap

Ryaltris™ - GSP 301

GBR 830

GBR 1302

Future Outlook
GBR 1302 Bispecific Antibody – Key Characteristics

Proprietary technology platform (BEAT®) for developing novel bi-specific antibodies – Tumor killing activity based on Redirected Lysis (RDL) of Tumor Cells by T cells

GBR 1302: HER2 X CD3

Key features of BEAT®

- **Efficiency** in transferring tumor antigen binding scFv’s into BEAT® format (“plug & play”)
- **Flexibility** beyond CD3-mediated engagement immunocytes
- **Robustness** and scalability of platform similar to standard mAb production

Heterodimeric BEAT CH3 interface

Programs such as GBR 1342 and GBR 1372 are based on similar structure and mechanism
Why Target HER2?

• HER2 is a validated target but not fully exploited

• Restricted expression on normal tissue favors immunotherapy approach

• Several HER2+ tumors are non-responsive to approved anti-HER2 therapies
  – Breast, Bladder, Endometrial, Gastric
  – Several non-responders have TILs (Tumor infiltrated lymphocytes)

• HER2 is a validated target in gastric and gastroesophageal junction cancers are prime indications for CD3 engagers due to high levels of TILs
GBR 1302 – Clinical Update

• Phase 1 Update
  – Dose escalation continues with clinical sites open in Europe and the U.S.
  – The study is currently recruiting HER2 positive patients in cohort 7.
  – Inclusion criteria: Progressive HER2 IHC-positive solid tumor with no available standard or curative treatment

• Primary Objectives: Maximum tolerated dose (MTD), Safety

• Secondary Objectives: Pharmacokinetics (PK) of single and repeated doses Immunogenicity. Anti-tumor activity, overall response rate (ORR), disease control rate (DCR), duration of response

• So far, 21 patients have been screened and 15 patients (including patients with gastric cancer, bladder cancer and breast cancer) have been dosed.
• In addition, GBR 1302 interim biomarker data and preclinical data is expected to be presented at medical meetings in CY 2018.
## Summary

### Glenmark in 2017
- 2 major geographies - US and India
- Revenue stream consisting of purely generics portfolio
- US, EU business based on substitution model
- NME pipeline in early to mid stages
- Manufacturing base primarily in India
- Profitability margin at ~20%

### Glenmark in 2021
- US, India, Europe and API to contribute >80% of sales
- Increased presence in complex generics
- Scaling up the specialty business in the US
- NME pipeline in advanced stage of development
- Global manufacturing footprint
- Profitability margin at ~23%

### Glenmark in 2025
- Launch of innovative products
- Specialty business ramp up in the US
- Specialty and Innovative segments to be the main growth drivers
- Increased presence in complex generics space
- Significant revenues from specialty and innovation segments
- Profitability margin at ~25%
THANK YOU